Industry Update: With Recent Success in Pre-Clinical Trials, Innocan Pharma is Poised to Disrupt Multi-Billion Dollar Pharma and Veterinary Industries (CNSX: INNO)
Innocan Pharma’s (CSE: INNO) (FSE: IP4) recent success in animal trials, alongside additional milestones reached over the past few months, position the company for immense growth as an emerging sectorial…